Isolations Sample Clauses

Isolations. Unless Customer opts-out, Critical Start will isolate potentially compromised machines. Critical Start will manually isolate the machine using the endpoint solution and notify Customer of the isolation via the alert write-up procedure for escalation. The machines will remain in isolation until the threat has been remediated or Customer has specifically indicated that they accept the risk and request Critical Start remove the isolation. Should Customer opt to have Critical Start remove isolation from an affected machine: (i) associated SLAs shall be suspended until the discovered threat has been remedied, and (ii) Customer shall waive all associated liability regarding the affected machine’s removal from isolation. Customer hereby commits to identifying production impacting servers and assets that are not to be isolated unless Customer has given written authorization. Critical Start commits to isolating machines that are not on the authorized list only to prevent the spread of malicious code and lateral movement by suspected attackers. Critical Start will escalate all alerts that require isolation to Customer for their visibility and active feedback on the alert. Customers using endpoint detection and response and/or endpoint protection solutions are advised that the MDR Services have the ability to isolate machines on Customer’s network and can use that functionality to protect Customer’s network. Isolated machines will lose all connectivity to all other devices on Customer’s network.
AutoNDA by SimpleDocs
Isolations. Unless Customer opts-out, Critical Start will isolate potentially compromised machines. Critical Start will manually isolate the machine using the endpoint solution and notify Customer of the isolation via the alert write-up procedure for escalation. The machines will remain in isolation until the threat has been remediated or Customer has specifically indicated that they accept the risk and request Critical Start remove the isolation. Should Customer opt to have Critical Start remove isolation from an affected machine: (i) associated SLAs shall be suspended until the discovered threat has been remedied, and (ii) Customer shall

Related to Isolations

  • Techniques Framework agreement: Information about the dynamic purchasing system: No dynamic purchase system

  • Elements Defines the individual components under each indicator

  • Processes Any employer, employee, trade union or employer’s association may at any point in time apply for an exemption from any of the provisions of this Collective Agreement. The applicant is required to complete and submit in writing with the relevant office of the Council, a fully and properly completed prescribed application for exemption form, accompanied by all relevant supporting documentation.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Devices BNY Mellon will restrict the transfer of Customer Data from its network to mass storage devices. BNY Mellon will use a mobile device management system or equivalent tool when mobile computing is used to provide the services. Applications on such authenticated devices will be housed within an encrypted container and BNY Mellon will maintain the ability to remote wipe the contents of the container.

  • Structures Airport facilities such as bridges; culverts; catch basins, inlets, retaining walls, cribbing; storm and sanitary sewer lines; water lines; underdrains; electrical ducts, manholes, handholes, lighting fixtures and bases; transformers; flexible and rigid pavements; navigational aids; buildings; vaults; and, other manmade features of the airport that may be encountered in the work and not otherwise classified herein. 10-50 SUBGRADE. The soil which forms the pavement foundation.

  • Compositions any corporate action, legal proceedings or other procedures or steps are taken, or negotiations commenced, by any Security Party or by any of its creditors with a view to the general readjustment or rescheduling of all or part of its Indebtedness or to proposing any kind of composition, compromise or arrangement involving such company and any of its creditors; or

  • Solicitations for Subcontracts, Including Procurements of Materials and Equipment In all solicitations either by competitive bidding or negotiation made by the Engineer for work to be performed under a subcontract, including procurements of materials or leases of equipment, each potential subcontractor or supplier shall be notified by the Engineer of the Engineer's obligations under this contract and the Regulations relative to nondiscrimination on the grounds of race, color, or national origin.

  • Sampling The Licensee agrees that the Composition is purchased as a “Work Made for Hire” whereby the clearing of any sampled materials is the responsibility of Licensee.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!